Key result
Takotsubo cardiomyopathy in oncology patients is linked to poorer outcomes versus the general population.
Why the study?
The pathophysiological mechanisms leading to Takotsubo cardiomyopathy in cancer patients are not entirely understood, and its diagnosis during cancer treatment can be challenging and often neglected.
Answers are grounded in this paper and cite their sources.
Alerts clinicians to monitor for Takotsubo in oncology patients; leaves open whether targeted interventions improve its poorer prognosis.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Macedo et al. (2022) conducted a review in Takotsubo Cardiomyopathy in Cancer Patients. Antineoplastic therapies and cancer-related stress was evaluated. Takotsubo cardiomyopathy in oncology patients is increasingly recognized as a cardiotoxic complication of cancer therapies and is associated with a poorer prognosis compared to the general population.
Synapse has enriched 10 related papers. Consider them for comparative context: